Home

  • English
  • Русский
Investment, scientific work, medicine, pharmacy,
development and production of medicines
 

Projects

STIMFORTE is our first product approved for complex treatment of secondary immunodeficient states caused by chronic bacterial and viral infections including genital herpes, recurrent furunculosis in Russia. Stimforte activates innate immunity through toll-like (TLR) receptors, mainly through TLR 4. SKY LTD has licensed the rights to develop and commercialize STIMFORTE in Europe and Asia. This product has potential for additional indications.

EBR-1- our candidate is currently in Phase 2 clinical trials for the treatment of endometriosis. Through preclinical phase in vivo candidate demonstrated significant induction of apoptosis, inhibition of angiogenesis in proliferate tissue. This product has potential for additional indications.

Product Indication Status
Stimforte Secondary immunodeficiency cased by chronic bacterial and viral infections Registered for clinical application in Russian Federation
Clinical trial for expansion of indications for treatment
(Hepatitis B, C)
EBR-1 Endometriosis Clinical trial Phase 2
инновационные лекарственные препараты, перспективные научные идеи

656015, Russia, Altai, Barnaul, Lenina str., 69
Tel: +7 (3852) 61-67-27, 61-23-00, 61-69-91 fax: +7 (3852) 24-75-60
e-mail: skyltd@ab.ru